<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3288242/0/en/Verrica-Pharmaceuticals-Announces-Upcoming-Presentation-of-Phase-2-Data-Highlighting-the-Potential-Abscopal-Effects-of-VP-315-in-the-Treatment-of-Basal-Cell-Carcinoma-at-the-2026-S.html">Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors  WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3287591/0/en/verrica-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-12-2026.html">Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/09/3271414/0/en/Verrica-Pharmaceuticals-Announces-Acceptance-of-Late-Breaking-Abstract-Highlighting-Potential-Abscopal-Effect-of-VP-315-for-the-Treatment-of-Basal-Cell-Carcinoma-at-the-Upcoming-20.html">Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica&#39;s novel oncolytic peptide for the treatme...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/06/3268395/0/en/Verrica-Pharmaceuticals-to-Participate-in-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html">Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needha...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260320302363/en/VRCA-Investor-News-Rosen-Law-Firm-Announces-Investigation-of-Breaches-of-Fiduciary-Duties-by-the-Directors-and-Officers-of-Verrica-Pharmaceuticals-Inc.-%E2%80%93-VRCA/">VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). If you currently own shares of Verrica Pharmaceuticals stock, please visit the firm&#39;s website at https://rosenlegal.com/submit-form/?case_id=6828 for more information. You ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Verrica-Pharmaceuticals-Inc-US92511W1080">Verrica Pharmaceuticals Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260319799766/en/Verrica-Pharmaceuticals-Investor-News-Rosen-Law-Firm-Announces-Investigation-of-Breaches-of-Fiduciary-Duties-by-the-Directors-and-Officers-of-Verrica-Pharmaceuticals-Inc.-%E2%80%93-VRCA/">Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA). If you currently own shares of Verrica Pharmaceuticals stock, please visit the firm&#39;s website at https://rosenlegal.com/submit-form/?case_id=6828 for more information. You ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Verrica-Pharmaceuticals-Inc-US92511W1080/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>